Drug
212pb PB Mp0712
212pb PB Mp0712: highest development phase Phase 1/2, developed by Molecular Partners. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Molecular Partners
Trials
| Drug | Phase | Indication |
|---|---|---|
| [212Pb]Pb-MP0712 NCT07278479 | Phase 1/2 | Large Cell Neuroendocrine Carcinoma |
Latest
No recent events.
Follow 212pb PB Mp0712 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.